HUTCHMED (00013): Announces Preclinical Data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
HUTCHMED (00013) announced that preclinical data for HMPL-A830 were presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics held in Barcelona, Spain, from November 18 to 20, 2026.
HMPL-A830 is a globally first-in-class antibody-targeted conjugate (ATTC) drug candidate, consisting of a highly selective and potent KRAS small molecule inhibitor as the payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody.
HUTCHMED (00013) announces that preclinical data for HMPL-A830 were presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held in Barcelona, Spain, from November 18 to 20, 2026.
HMPL-A830 is a first-in-class antibody-targeted conjugate drug (ATTC) candidate, composed of a highly selective and potent KRAS small molecule inhibitor as the payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody.
RAS mutations are among the most common and well-defined drivers in human oncology, driving the progression and aggressive pathological features of multiple solid tumors. Although targeted therapies emerging in recent years have confirmed KRAS (the most predominant RAS isoform) as a viable therapeutic target, significant unmet clinical needs remain, including safety limitations and disease progression due to acquired resistance, which is mostly mediated by upregulation of upstream receptor tyrosine kinases. HMPL-A830 is designed to address this unmet medical need by delivering a KRAS inhibitor directly to EGFR-expressing tumors while simultaneously blocking both EGFR and KRAS signaling pathways, thereby enhancing efficacy, durability, and tolerability.
In vitro studies showed that its pan-KRAS payload has a dual mechanism of action, blocking both the active (ON) state (i.e., GTP-RAF1 binding) and the inactive (OFF) state (i.e., GDP-to-GTP conversion) of KRAS. Potent antiproliferative activity was observed across 55 tumor cell lines covering various KRAS alterations, including G12C, G12D, G12V, and G13D mutations as well as wild-type amplification. HMPL-A830 exhibits high affinity for EGFR-positive cells and is rapidly internalized into cells. In addition, it demonstrates a strong bystander killing effect, effectively eliminating adjacent EGFR-negative tumor cells while preserving potent antibody-dependent cell-mediated cytotoxicity (ADCC).
In mouse models, HMPL-A830 demonstrated potent, dose-dependent antitumor efficacy across multiple EGFR-positive tumor models carrying KRAS alterations. Compared with KRAS G12C inhibitors, HMPL-A830 achieved more durable tumor regression; its efficacy was also superior to multiple control regimens, including its unconjugated antibody, pan-RAS inhibitors (as monotherapy or in combination with cetuximab), and an antibody-drug conjugate (ADC) targeting TROP2 with a topoisomerase I (Topo I) inhibitor. Pharmacokinetic/pharmacodynamic analyses showed that, compared with the naked antibody, HMPL-A830 had stronger and more durable inhibition of EGFR/KRAS downstream signaling pathways; in addition, the drug maintained a stable drug-to-antibody ratio (DAR) in mouse, monkey, and human plasma.
In September 2026, the Company's subsidiary HUTCHMED Limited and a subsidiary of GSK plc reached an exclusive development and license agreement granting the GSK subsidiary the rights to develop and commercialize HMPL-A830 worldwide excluding Mainland China, Hong Kong, Macau, and Taiwan. HUTCHMED Limited will be responsible for the global Phase I development program of HMPL-A830. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities in territories outside Mainland China, Hong Kong, Macau, and Taiwan.
An ongoing global Phase I clinical trial is currently in the Phase Ia stage, designed to evaluate the safety and efficacy of HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).
Related Articles

SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.
SA SA INT'L (00178) will pay an interim dividend of HK$0.04 per share on December 18.

SSY GROUP (02005): Low-calcium Peritoneal Dialysis Solution (Bicarbonate G1.5%) and Other Drugs Obtain Drug Production Registration Approval

SA SA INT'L (00178) announces interim results, profit attributable to shareholders HK$170 million, up 239.14% year-on-year; sales performance in core markets Hong Kong and Macau improved significantly.






